Company Focus

Alnylam Pharmaceuticals

Latest Alnylam Pharmaceuticals News

Vutrisiran nod sets stage for shake-up in rare disease space
Pharmaceutical
Alnylam Pharmaceuticals has won European Commission approval for Amvuttra (vutrisiran) to treat transthyretin amyloidosis with cardiomyopathy (ATTR-CM), positioning the drug as a likely challenger to entrenched therapies in a market expected to see rapid evolution.   2 July 2025


Latest News & Features of interest to Alnylam Pharmaceuticals

Latest In Brief for Alnylam Pharmaceuticals

Pharmaceutical
Ireland-based biopharma Jazz Pharmaceuticals has been called out for a couple of indiscretions by The Prescription Medicines Code of Practice Authority (PMCPA), which was established by the Association of the British Pharmaceutical Industry (ABPI) to operate the ABPI Code of Practice for the Pharmaceutical Industry.   11 July 2025

Latest Relevant Ones To Watch News

Theratechnologies, a Canada-based biopharma, is to be acquired by CB Biotechnology, an affiliate of Future Pak, a privately-held contract manufacturer, packager and distributor of pharmaceutical and nutraceutical products.   4 July 2025

More in M&A >


Relevant Ones to Watch Companies

Reset all filters
Refine Search